Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

SABCS 2010

8 - 12 Dec 2010

Published: 18 Jan 2011

Views: 5269

Rating:

Save

Prof Luca Gianni - Fondazione IRCCS Istituto Tumori di Milano, Italy

The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Details of these study results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010.

Categories:
Breast

Related Videos

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

Exercise positively effects symptom burden and quality of life of metastatic...

Dr Anouk Hiensch - UMC Utrecht, Utrecht, Netherlands

Exercise positively effects symptom burden and quality of life of metastatic breast cancer patients ( Dr Anouk Hiensch - UMC Utrecht, Utrecht, Netherlands )

Using AI to identify patients at increased risk of side effects from radiation...

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )

Implementation of the Choosing Wisely Africa List in 3 Countries

Dr Sarah Kutika Nyagabona - Muhimbili National Hospital, Dar es Salaam, Tanzania

Implementation of the Choosing Wisely Africa List in 3 Countries ( Dr Sarah Kutika Nyagabona - Muhimbili National Hospital, Dar es Salaam, Tanzania )

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple...

Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy ( Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium )

T-DM1 shows promise in treating unresectable locally advanced or metastatic...

Dr Sara Hurvitz - University of Washington, Seattle, USA

T-DM1 shows promise in treating unresectable locally advanced or metastatic HER2-positive breast cancer ( Dr Sara Hurvitz - University of Washington, Seattle, USA )

ASCO and its Sub-Saharan African outreach programme

Dr Julie Gralow - Chief Medical Officer, American Society of Clinical Oncology...

ASCO and its Sub-Saharan African outreach programme ( Dr Julie Gralow - Chief Medical Officer, American Society of Clinical Oncology (ASCO), USA )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

SABCS 2023: Highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2023: Highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

More from ecancer